(RTTNews) - Percheron Therapeutics Ltd. (PER.AX) said Monday the U.S. Food and Drug Administration cleared an investigator-sponsored trial of HMBD-002 with venetoclax and azacitidine in acute myeloid leukemia and myelodysplastic syndrome (MDS).